NXI Therapeutics develops next-gen immunosuppressive drugs for autoimmune diseases and organ transplantation.
NXI Therapeutics has raised $4.0M in total funding. The most recent round was Pre-Seed. The last funding was announced in June 2024.
NXI Therapeutics's investors include Kickfund, Venture Kick, BaseLaunch, Gebert Rüf Stiftung, University of Basel.
NXI Therapeutics is headquartered in Basel, Switzerland.
NXI Therapeutics develops next-gen immunosuppressive drugs for autoimmune diseases and organ transplantation.
NXI Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NXI Therapeutics — Funding & Investors." VCBacked, June 18, 2024, https://www.vcbacked.co/company/nxi-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). NXI Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nxi-therapeutics
{{cite web |title=NXI Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nxi-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated